Search research articles
Contact Us
Filters
Showing results (181-190 of 192) with videos related to
Page
of 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Valentina Ambrosini, Jolanta Kunikowska, Eric Baudin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2019
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Ángela Lamarca, et al.
Thyroid : Official Journal of the American Thyroid Association
|
March 6, 2025
DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer
Helena Rodríguez-Lloveras, Carles Zafon, Carmela Iglesias, et al.
Lancet (London, England)
|
July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
Thomas Walter, Henning Jann, Catherine Ansquer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 3, 2020
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial
Maxime J M van der Valk, Corrie A M Marijnen, Boudewijn van Etten, et al.
Neuroendocrinology
|
June 22, 2026
Proximal-to-distal gradient and its implications in differentiation and prognosis in colorectal neuroendocrine neoplasms: the RGETNE-HERACLES study
Germán Iglesias Álvarez, Jaume Capdevila, Rocio Garcia-Carbonero, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 28, 2020
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Antonio Viúdez, Guillermo Crespo, María Luisa Gómez Dorronsoro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trials
Alice Rossi, Irene Braña, Maria Vieito, et al.
Med (New York, N.Y.)
|
August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
BMC Cancer
|
April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 192) with videos related to
Sort By:
Page
of 20
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Valentina Ambrosini, Jolanta Kunikowska, Eric Baudin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2019
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Ángela Lamarca, et al.
Thyroid : Official Journal of the American Thyroid Association
|
March 6, 2025
DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer
Helena Rodríguez-Lloveras, Carles Zafon, Carmela Iglesias, et al.
Lancet (London, England)
|
July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
Thomas Walter, Henning Jann, Catherine Ansquer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 3, 2020
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial
Maxime J M van der Valk, Corrie A M Marijnen, Boudewijn van Etten, et al.
Neuroendocrinology
|
June 22, 2026
Proximal-to-distal gradient and its implications in differentiation and prognosis in colorectal neuroendocrine neoplasms: the RGETNE-HERACLES study
Germán Iglesias Álvarez, Jaume Capdevila, Rocio Garcia-Carbonero, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 28, 2020
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Antonio Viúdez, Guillermo Crespo, María Luisa Gómez Dorronsoro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trials
Alice Rossi, Irene Braña, Maria Vieito, et al.
Med (New York, N.Y.)
|
August 12, 2023
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, et al.
BMC Cancer
|
April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Page
of 20